A randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil/hydroxyurea [hydroxycarbamide] compared to FHX plus bevacizumab for intermediate stage and selected stage IV cancers of the head and neck

Trial Profile

A randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil/hydroxyurea [hydroxycarbamide] compared to FHX plus bevacizumab for intermediate stage and selected stage IV cancers of the head and neck

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2012

At a glance

  • Drugs Bevacizumab; Fluorouracil; Hydroxycarbamide
  • Indications Head and neck cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 09 Jun 2011 Planned End Date changed from 1 Dec 2009 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 17 Feb 2011 Status changed from active, no longer recruiting to discontinued.
    • 17 Feb 2011 This trial was halted following unexpected locoregional progression in the bevacizumab group in patients with T4N0-1 tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top